NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

被引：0

作者：

Tan, Antoinette R.

Buyse, Marc E.

Rastogi, Priya

Jacobs, Samuel A.

Robidoux, Andre

Flynn, Patrick J.

Thirlwell, Michael P.

Fehrenbacher, Louis

Stella, Philip J.

Goel, Rakesh

Julian, Thomas B.

Provencher, Louise

Bury, Martin Joseph

Paik, Soonmyung

Geyer, Charles E.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, New Brunswick, NJ USA

[2] Canc Inst New Jersey, New Brunswick, NJ USA

[3] Int Inst Drug Dev, Louvain, Belgium

[4] NSABP, Pittsburgh, PA USA

[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[6] NSABP, Montreal, PQ, Canada

[7] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[8] NSABP, St Louis Pk, MN USA

[9] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA

[10] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada

[11] NSABP, Vallejo, CA USA

[12] Kaiser Permanente Northern Calif, Vallejo, CA USA

[13] NSABP, Ann Arbor, MI USA

[14] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA

[15] NSABP, Ottawa, ON, Canada

[16] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[17] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA

[18] NSABP, Quebec City, PQ, Canada

[19] Ctr Hosp Affilie Univ Quebec, Hop St Sacrement, Quebec City, PQ 75390, Canada

[20] NSABP, Grand Rapids, MI USA

[21] Grand Rapids Clin Oncol Program, Grand Rapids, MI USA

[22] NSABP, Dallas, TX USA

[23] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[24] NSABP, Washington, DC USA

[25] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[26] NSABP, Canton, OH USA

[27] Aultman Hosp, Canton, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1025

引用

页数：1

共 50 条

[11] Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute
Yardley, D. A.
Hainsworth, J. D.
Shastry, M.
Finney, L.
Burns, H. A.
CANCER RESEARCH, 2012, 72
[12] NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N plus T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
Jacobs, S. A.
Robidoux, A.
Garcia, J. M. P.
Abraham, J.
La Verde, N.
Orcutt, J. M.
Cazzaniga, M. E.
Calvo, L.
Aguirre, E.
Buyse, M.
Pogue-Geile, K. L.
Srinivasan, A.
Song, N.
Balousek, A. D.
Wolmark, N.
CANCER RESEARCH, 2016, 76
[13] Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute
Yardley, Denise
Dyehouse, Karyn
Mani, Aruna
Calfa, Carmen
Drosick, David
Yost, Kathleen
Shipley, Diana
Quinn, Raven
Young, Robyn
Finney, Lindsey
Earwood, Chris
Shastry, Mythili
Hainsworth, John
CANCER RESEARCH, 2015, 75
[14] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Tampaki, Ekaterini C.
Tampakis, Athanasios
Alifieris, Constantinos E.
Krikelis, Dimitrios
Pazaiti, Anastasia
Kontos, Michalis
Trafalis, Dimitrios T.
CLINICAL DRUG INVESTIGATION, 2018, 38 (07) : 639 - 648
[15] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Ekaterini C. Tampaki
Athanasios Tampakis
Constantinos E. Alifieris
Dimitrios Krikelis
Anastasia Pazaiti
Michalis Kontos
Dimitrios T. Trafalis
Clinical Drug Investigation, 2018, 38 : 639 - 648
[16] Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC- T) in triple negative locally advanced breast cancer (LABC) in Brazil
Nunes, J. S.
Tsunoda, A. T.
Viana, L. S.
Souza, F. H.
Castro, N.
Hohmann, J.
Serrano, S. V.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[17] Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2- Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group
Rastogi, Priya
Buyse, Marc E.
Swain, Sandra M.
Jacobs, Samuel A.
Robidoux, Andre
Liepman, Marcia K.
Pajon, Eduardo R.
Dy, Philip A.
Posada, Juan G., Jr.
Melnik, Marianne K.
Piette, Fanny
Geyer, Charles E., Jr.
Mamounas, Elfetherios P.
Wolmark, Norman
CLINICAL BREAST CANCER, 2011, 11 (04) : 228 - 234
[18] Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of biweekly doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple-negative (TN), HER2-neu-positive (HER2+), or locally advanced breast cancer (LABC): Preliminary results of a prospective, phase II, nonrandomized study.
Vassilaki, M.
Sioulas, A.
Tsantekidou, M.
Klitsa, A.
Desses, N.
Georgakopoulos, C.
Thomou, P.
Xepapadakis, G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[19] A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer
Lynce, Filipa
Yeh, Eren D.
Regan, Meredith M.
Qin, Lei
Bay, Camden P.
Krop, Ian
Harrison, Beth T.
Nakhlis, Faina
Bellon, Jennifer
Overmoyer, Beth
CANCER RESEARCH, 2022, 82 (04)
[20] A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
Yardley, Denise A.
Shipley, Dianna
Zubkus, John
Wright, Gail L.
Ward, Patrick J.
Mani, Aruna
Shastry, Mythili
Finney, Lindsey
DeBusk, Laura
Hainsworth, John D.
CLINICAL BREAST CANCER, 2019, 19 (01) : 1 - 9

← 1 2 3 4 5 →